Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas
November 22, 2021
November 22, 2021
November 12, 2021
November 10, 2021
November 9, 2021
November 8, 2021
November 4, 2021
November 4, 2021
October 29, 2021
October 1, 2021
September 8, 2021